Total number of patients commenced on sacubtril/valsartan

n=44

Male

Average Age (years)

36 (82%)

64 years

NYHA class improvement (>1 class)

Target dose up-titration achieved (97/103 mg)

12 (27%)

25 (57%)

Drop of systolic Blood Pressure at follow-up (>10 mmHg)

Hyperkalaemia (>6.0 mmol/L)

9 (20%)

3 (7%)*

*(1 patient hospital admission due to hyperkalaemia)

Mortality and morbidity

2 (5%) in-hospital deaths* and 1 HF hospital admission

*(1 due to progressive HF, 1 non CV-related hospital admission and death)

Sacubtril/valsartan intolerability and stopped

2 (5%)

(reported dizziness and abdominal pain)

Deterioration in eGFR>10

4 (9%)